Yang Kun-Lin, Hung Kuo-Chen, Chang Wen-Teng, Li Eric I C
Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.
Comp Hepatol. 2007 Oct 19;6:9. doi: 10.1186/1476-5926-6-9.
Liver fibrosis represents a significant and severe health care problem and there are no efficient drugs for therapy so far. Preventing the progression of fibrogenesis and revival endogenous repair activities is an important strategy for both current and future therapies. Many studies of liver fibrosis consist of animal testing with various hepatotoxins. Although this method is often used, the model at which cirrhosis or extensive fibrosis becomes irreversible has not been well defined and is not representative of early-stage fibrogenesis. We here report the establishment of a transient and reversible liver fibrosis animal model which may better represent an early and natural fibrotic event. We used a high-speed intravenous injection of naked plasmid DNA of transforming growth factor-beta1 (TGF-beta1) gene which is under the control of a metallothionein-regulated gene in a pPK9A expression vector into the tail vein (the hydrodynamics-based transfer) and fed the mouse with zinc sulfate (ZnSO4)-containing water simultaneously.
Using our hydrodynamics-based gene transfer model we found that upon induction by ZnSO4, the serum TGF-beta1 level in Balb/c mice and Sp1 transcription factor binding activity peaked at 48 h and declined thereafter to a normal level on the 5th day. In addition, mRNA and protein levels of TGF-beta1 in the liver were also upregulated at 48 h. Furthermore, induction of TGF-beta1 increased the alpha-smooth muscle actin (alpha-SMA), p-Smad2/3, hydroxyproline and collagen 1A2 (Col 1A2) levels in the liver, suggesting a significant liver fibrosis.
Our results show that TGF-beta1 in pPK9a-transferred mice liver with ZnSO4 feeding can achieve a high expression level with significant fibrosis. However, since TGF-beta1 induction is transient in our model, the fibrotic level does not reach a large scale (panlobular fibrosis) as seen in the CCl4-treated liver. Our model hence represents a dynamic and reversible liver fibrosis and could be a useful tool for studying early molecular mechanism of fibrogenesis or screening of antifibrotic drugs for clinical use.
肝纤维化是一个重大且严重的医疗保健问题,目前尚无有效的治疗药物。防止纤维化进程并恢复内源性修复活动是当前和未来治疗的重要策略。许多肝纤维化研究包括使用各种肝毒素进行动物试验。虽然这种方法经常被使用,但肝硬化或广泛纤维化变得不可逆的模型尚未得到很好的定义,也不能代表早期纤维化形成。我们在此报告建立了一种短暂且可逆的肝纤维化动物模型,该模型可能更好地代表早期和自然的纤维化事件。我们通过尾静脉将处于金属硫蛋白调控基因控制下的转化生长因子-β1(TGF-β1)基因的裸质粒DNA以高速静脉注射的方式(基于流体动力学的转移)注入pPK9A表达载体中,并同时给小鼠喂食含硫酸锌(ZnSO4)的水。
使用我们基于流体动力学的基因转移模型,我们发现经硫酸锌诱导后,Balb/c小鼠血清TGF-β1水平和Sp1转录因子结合活性在48小时达到峰值,此后下降,在第5天恢复到正常水平。此外,肝脏中TGF-β1的mRNA和蛋白质水平在48小时也上调。此外,TGF-β1的诱导增加了肝脏中α-平滑肌肌动蛋白(α-SMA)、磷酸化Smad2/3、羟脯氨酸和胶原蛋白1A2(Col 1A2)的水平,表明存在明显的肝纤维化。
我们的结果表明,在喂食硫酸锌的pPK9a转染小鼠肝脏中,TGF-β1可实现高表达水平并伴有明显纤维化。然而,由于在我们的模型中TGF-β1的诱导是短暂的,纤维化程度未达到在四氯化碳处理的肝脏中所见的大规模(全小叶纤维化)。因此,我们的模型代表了一种动态且可逆的肝纤维化,可能是研究纤维化形成早期分子机制或筛选临床使用的抗纤维化药物的有用工具。